ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Rheumatic disease"

  • Abstract Number: 286 • 2018 ACR/ARHP Annual Meeting

    The Prevalence and Treatment Patterns of Women of Childbearing Age with Rheumatic Diseases

    Edward Lee1, Robert Suruki2, Brian Carpenter3, Ty Harkness3, Daniel Luk4 and Mohamed Yassine1, 1UCB Pharma, Smyrna, GA, 2UCB Pharma, Raleigh, NC, 3Charles River Associates, New York, NY, 4Charles River Associates, Boston, MA

    Background/Purpose: Emerging data on exposure of infants to therapeutics through placental transfer and breastmilk could impact the management of women of childbearing age (WoCBA) with…
  • Abstract Number: 81 • 2017 ACR/ARHP Annual Meeting

    Selective Inhibition of the Immunoproteasome Subunit LMP7 Is Not Sufficient for Blocking Cytokine Production or Attenuating Progression of Experimental Arthritis

    Eric Lowe1, Janet Anderl1, R Andrea Fan1, Henry W. B. Johnson2, Christopher J Kirk3 and Tony Muchamuel4, 1Biology, Kezar Life Sciences, South San Francisco, CA, 2Medicinal Chemistry, Kezar Life Sciences, South San Francisco, CA, 3Kezar Life Sciences, South San Francisco, CA, 4Pharmacology and Toxicology, Kezar Life Sciences, South San Francisco, CA

    Background/Purpose: The proteasome inhibitor (PI) PR-957/ONX 0914 blocks cytokine production in vitro and attenuates disease progression in experimental models of rheumatoid arthritis (RA) (Nature Medicine…
  • Abstract Number: 509 • 2017 ACR/ARHP Annual Meeting

    Long-Term Safety and Efficacy of Upadacitinib (ABT-494), an Oral JAK-1 Inhibitor in Patients with Rheumatoid Arthritis in an Open Label Extension Study

    Mark C. Genovese1, Joel Kremer2, Sheng Zhong3 and Alan Friedman3, 1Stanford University Medical Center, Palo Alto, CA, 2Albany Medical College, Albany, NY, 3AbbVie Inc., North Chicago, IL

    Background/Purpose: Upadacitinib (UPA, ABT-494) is a selective, oral JAK-1 inhibitor studied in two phase 2 randomized controlled trials (RCTs) in patients (pts) with rheumatoid arthritis…
  • Abstract Number: 536 • 2017 ACR/ARHP Annual Meeting

    Effectiveness, Tolerability, and Safety of Tofacitinib in Rheumatoid Arthritis: A Retrospective Analysis of Real-World Data from the St. Gallen Cohort

    Ruediger Mueller1, Frederik Mattow2, Florian Popp3 and Johannes von Kempis4, 1Division of Rheumatology, Cantonal Hospital, St. Gallen, Switzerland, 2Kantonsspital St. Gallen, St. Gallen, Switzerland, 3Rorschacherstrasse 95, Kantonsspital St. Gallen, St. Gallen, Switzerland, 4Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland

    Background/Purpose: Tofacitinib is an oral JAK inhibitor for the treatment of RA. Efficacy and safety of tofacitinib have been shown in several clinical studies. The…
  • Abstract Number: 1299 • 2017 ACR/ARHP Annual Meeting

    Patient-Reported Disease Activity and Adverse Pregnancy Outcomes in Systemic Lupus Erythematosus and Rheumatoid Arthritis

    Nathaniel Harris1, Amanda M. Eudy2 and Megan E. B. Clowse2, 1Duke University School of Medicine, Durham, NC, 2Division of Rheumatology, Department of Medicine, Duke University Medical Center, Durham, NC

    Background/Purpose: Patient-reported measures of disease activity may provide useful adjuncts to physician-reported measures in identifying pregnancies at greater risk for adverse pregnancy outcomes. Little is…
  • Abstract Number: 118 • 2017 Pediatric Rheumatology Symposium

    Oxygen Saturation Recordings in Pediatric Rheumatology Patients At Risk For Lung Disease

    Rebecca Trachtman1, Alexa Adams2, Nancy Pan2, Sarah Taber2 and Karen Onel2, 1Pediatric Rheumatology, Hospital for Special Surgery Weill Cornell Medical College, NY, NY, 2Pediatric Rheumatology, Hospital for Special Surgery Weill Cornell Medical College, New York, NY

    Background/Purpose: Pediatric rheumatology patients are at high risk for the development of pulmonary disease. Lung disease in these patients can go unnoticed for long periods…
  • Abstract Number: 438 • 2016 ACR/ARHP Annual Meeting

    Glucocorticoid Adverse Effects – the Patient Perspective

    Rachel Black1, Susan M. Goodman2, Carlee Ruediger3, Susan Lester4, Sarah Mackie5 and Catherine Hill3, 1Department of Medicine, The University of Adelaide, Adelaide, Australia, 2Medicine, Hospital for Special Surgery, New York, NY, 3Medicine, The University of Adelaide, Adelaide, Australia, 4Rheumatology, Queen Elizabeth Hospital, Woodville South, Australia, 5NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, University of Leeds, Leeds, United Kingdom

    Background/Purpose: Glucocorticoid (GC) use and adverse effects (AEs) are prevalent in rheumatic diseases, yet there is no standardized patient-reported outcome measure to assess benefit and…
  • Abstract Number: 932 • 2016 ACR/ARHP Annual Meeting

    High Symptom Prevalence and Under-Utilisation of Palliative Care at End-of-Life of Patients with Systemic Rheumatic Diseases

    Jiacai Cho1, Dominic Lo2, Anselm Mak1,2, Jamie Zhou3 and Sen Hee Tay1,2, 1Division of Rheumatology, Department of Medicine, National University Hospital, National University Health System, Singapore, Singapore, Singapore, 2Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, Singapore, 3Department of Haematology-Oncology, National University Cancer Institute, National University Hospital, National University Health System, Singapore, Singapore, Singapore

    Background/Purpose: Patients with rheumatic diseases may have systemic complications from disease as well as therapy and often suffer symptoms towards the end-of-life comparable to patients…
  • Abstract Number: 1352 • 2016 ACR/ARHP Annual Meeting

    Predictors of Mortality in Rheumatic Disease Patients with CMV Infection

    Kyoung Yong Lee1, Seung Min Jung1, Sang-Won Lee2, Yong-Beom Park2 and Jason Jungsik Song2, 1Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, The Republic of, 2Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea

    Background/Purpose: Immunosuppressive therapy, which is frequently used to treat various rheumatic diseases, increases risk of opportunistic infection. However, few reports were available on the prognosis…
  • Abstract Number: 2458 • 2016 ACR/ARHP Annual Meeting

    Erectile Dysfunction in Men with Rheumatic Diseases: A Systematic Review

    Omid Zahedi Niaki1, Christian A. Pineau2, Sasha Bernatsky3,4 and Evelyne Vinet3, 1Université de Montréal, Montreal, QC, Canada, 2McGill University Health Centre, Montreal, QC, Canada, 3Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, 4Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada

    Background/Purpose: Given the obvious female predominance of rheumatic diseases, significant attention has already been drawn to the impact of these conditions on female sexual function.…
  • Abstract Number: 3023 • 2016 ACR/ARHP Annual Meeting

    Lipid Profile and Effect of Statin Treatment in Pooled Phase 2 and Phase 3 Baricitinib Studies

    Iain B. McInnes1, Joel Kremer2, Paul Emery3, Steven H. Zuckerman4, Giacomo Ruotolo4, Chadi Saifan4, Lei Chen4, Shayami Thanabalasundrum4, Sarah Witt4 and William Macias4, 1Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, Great Britain, 2The Center for Rheumatology, Albany Medical College, Albany, NY, 3University of Leeds, Midlothian, United Kingdom, 4Eli Lilly and Company, Indianapolis, IN

    Background/Purpose: In patients with active RA an increase in lipid analytes has been observed after treatment with janus kinase inhibitors and other disease-modifying antirheumatic drugs.1…
  • Abstract Number: 1215 • 2015 ACR/ARHP Annual Meeting

    Air Pollution and the Rheumatic Diseases: A Systematic Review and Meta-Analysis

    Gavin Sun1, Glen Hazlewood2, Sasha Bernatsky3, Gilaad Kaplan4, Bertus Eksteen5 and Cheryl Barnabe2, 1Department of Internal Medicine, University of Calgary, Calgary, AB, Canada, 2Division of Rheumatology, University of Calgary, Calgary, AB, Canada, 3Rheum/Clin. Epid., McGill MUHC/RVH, Montreal, QC, Canada, 4Division of Gastroenterology, University of Calgary, Calgary, AB, Canada, 5Division of Hepatology, University of Calgary, Calgary, AB, Canada

    Background/Purpose: Environmental risk factors, such as air pollution, have been studied in relation to the risk of development of rheumatic diseases, including rheumatoid arthritis (RA),…
  • Abstract Number: 1352 • 2015 ACR/ARHP Annual Meeting

    How Frequently Does Tuberculosis Screening Test Become Positive in Rheumatic Patients Treated with ANTI-Tumor Necrosis Factor-ALPHA Therapy? an Analysis of Risk Factors

    Jorge Gaspar Ramos1, Dafhne Miranda2, Pilar Cruz-Dominguez3, Luis Javier Jara4 and Miguel A. Saavedra5, 1Rheumatology, Hospital de Especialidades, Dr. Antonio Fraga Mouret, Centro Medico Nacional La Raza, IMSS, Mexico City, Mexico, 2Rheumatology, Rheumatology Unit, Hospital de Especialidades. Centro Médico La Raza, IMSS, Distrito federal, Mexico, 3Centro Médico Nacional La Raza IMSS, México, Mexico, 4Instituto Mexicano del Seguro Social, Mexico City, Mexico, 5Reumatología, Centro Médico Nacional La Raza IMSS, México DF., México D.F., Mexico

    Background/Purpose: Anti-tumor necrosis factor-α (TNF-α) therapy is associated with an increased risk of mycobacterium tuberculosis infection. Tuberculosis (TB) reactivation can lead to severe complications in…
  • Abstract Number: 1888 • 2015 ACR/ARHP Annual Meeting

    There Is a Need for New Systemic Sclerosis Subset Criteria: A Content Analytic Approach

    Sindhu Johnson1, Medha Soowamber2, Jaap Fransen3, Dinesh Khanna4, Frank H.J. van den Hoogen5, Murray Baron6, Marco Matucci Cerinic7, Christopher P. Denton8, Thomas A. Medsger Jr.9, Patricia E. Carreira10, Gabriela Riemekasten11, Jorg HW. Distler12, Armando Gabrielli13, Virginia D. Steen14, Lorinda Chung15, Richard Silver16, John Varga17, Ulf Müller-Ladner18, Madelon C. Vonk19, Ulrich A. Walker20, Frank Wollheim21, Ariane L. Herrick22, Daniel E. Furst23, Lazlo Czirjak24, Otylia Kowal-Bielecka25, Francesco Del Galdo26, Maurizio Cutolo27, Nicolas Hunzelmann28, Charles Murray29, Ivan Foeldvari30, Luc Mouthon31, Nemanja Damjanov32, Bashar Kahaleh33, Tracy M. Frech34, Shervin Assassi35, Lesley Ann Saketkoo36 and Janet E. Pope37, 1Toronto Scleroderma Program, Toronto Western Hospital, Mount Sinai Hospital, University of Toronto, University Health Network Pulmonary Hypertension Programme, Toronto, ON, Canada, 2Rheumatology, University of Toronto/ Toronto Western Hospital, Toronto, ON, Canada, 3Rheumatology, Radboud University Medical Centre, Nijmegen, Netherlands, 4Medicine, University of Michigan, Ann Arbor, MI, 5Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, 6Pavillion A, Rm 216, Jewish General Hospital, Montreal, QC, Canada, 7Department of BioMedicine, Division of Rheumatology, Transition Unit, University of Florence, Firenze, Italy, 8Centre for Rheumatology, Royal Free Hospital, London, United Kingdom, 9Medicine/Rheumatology, Univ of Pittsburgh, Pittsburgh, PA, 10Department of Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, 11Rheumatology, Human medicine, BERLIN, Germany, 12Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, 13Clinica Medica, Università Politecnica delle Marche, Ancona, Italy, 14Rheumatology, Georgetown University Medical Center, Washington, DC, 15Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, 16Div Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, 17Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, 18Rheumatology, Internal Medicine, Bad Nauheim, Germany, 19Rheumatology, Rheumatology, Nijmegen, Netherlands, 20Rheumatology, Systemic Sclerosis, Basel, Switzerland, 21Rheumatology, Lund University Hospital, Lund, Sweden, 22Centre for Musculoskeletal Research, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, 23Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 24University of Pécs Medical Center, Pécs, Hungary, 25Department of Rheumatology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland, 26University of Leeds, Leeds, United Kingdom, 27Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genova, Italy, 28Department of Dermatology, University of Cologne, Cologne, Germany, 29Department of Gastroenterology, Royal Free Hospital, London, United Kingdom, 30Rheumatology, Hamburg, Germany, 31Department of Internal Medicine, Department of Internal Medicine, Cochin Hospital, Referent Center for Necrotizing Vasculitis and Systemic Sclerosis, Paris-Descartes University, AP-HP, Paris, France, 32Resavska 69, Institute of Rheumatology, Belgrade, Serbia, 33Medicine/Rheumatology, The University of Toledo, Toledo, OH, 34Div of Rheumatology, University of Utah Medical Ctr, Salt Lake City, UT, 35Rheumatology, University of Texas Medical School at Houston, Houston, TX, 36Tulane University Lung Center, New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, 37University of Western Ontario, London, ON, Canada

    Background/Purpose: Systemic sclerosis (SSc) is a family of diseases unified by the presence of immune activation, vasculopathy and fibrosis. The concept of SSc subsets cannot…
  • Abstract Number: 2525 • 2015 ACR/ARHP Annual Meeting

    Patterns and Secular Trends in Use of Immunosuppressive Agents during Pregnancy in Women with Rheumatologic Conditions

    Rishi J. Desai1, Krista Huybrechts2, Brian Bateman2, Sonia Hernandez-diaz3, Helen Mogun2, Chandrasekar Gopalakrishnan4, Elisabetta Patorno4 and Seoyoung C. Kim5, 1Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, 2Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, MA, 3Harvard School of Public Health, Boston, MA, 4Brigham and Women's Hospital, Boston, MA, 5Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Systemic inflammatory conditions such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS) affect many women during their…
  • « Previous Page
  • 1
  • 2
  • 3
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology